GC
EWTX icon

Guggenheim Capital’s Edgewise Therapeutics EWTX Stock Holding History

Guggenheim Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$363K Buy
11,524
+953
+9% +$27.5K ﹤0.01% 1314
2025
Q4 		$262K Buy
+10,571
New +$212K ﹤0.01% 1586

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Guggenheim Capital's EWTX Position: Q1 2026 in Review

Guggenheim Capital increased its Edgewise Therapeutics (EWTX) stake by 9% in Q1 2026, buying an estimated $27.5K and bringing the position to 11,524 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Guggenheim Capital first reported a position in EWTX in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Guggenheim Capital held 11,524 shares of Edgewise Therapeutics worth $363K as of Q1 2026.
  • Guggenheim Capital bought 953 Edgewise Therapeutics shares in Q1 2026, an estimated $27.5K.
  • Edgewise Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1314 holding.
  • Guggenheim Capital first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.